Cited by 5,735Prostate Cancer Treatment and ResearchBone health and treatmentsProstate Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, Ian F., de Wit, Ronald, Berry, William R., Horti, Jozsef, Pluzanska, Anna, Chi, Kim N., Oudard, Stephane, Théodore, Christine, James, Nicholas D., Turesson, Ingela, Rosenthal, Mark A., Eisenberger, Mario A.·2004·New England Journal of Medicine

DOI 10.1056/nejmoa040720

Open this paper in CoChat — free account

Abstract

BACKGROUND: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease. METHODS: From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. The primary end point was overall survival. Secondary end points were pain, prostate-specific antigen (PSA) levels, and the quality of life. All statistical comparisons were against mitoxantrone. RESULTS: As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test) and those given weekly docetaxel had a hazard ratio for death of 0.91 (95 percent confidence interval, 0.75 to 1.11; P=0.36). The median survival was 16.5 months in the mitoxantrone group, 18.9 months in the group given docetaxel every 3 weeks, and 17.4 months in the group given weekly docetaxel. Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone); 22 percent, 35 percent (P=0.01), and 31 percent (P=0.08) had predefined reductions in pain; and 13 percent, 22 percent (P=0.009), and 23 percent (P=0.005) had improvements in the quality of life. Adverse events were also more common in the groups that received docetaxel. CONCLUSIONS: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone.

Integrity signals

Registry

Crossref · 10.1056/nejmoa040720

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The McGill Pain Questionnaire: Major properties and scoring methods
Melzack, R. (1975) · Pain · doi:10.1016/0304-3959(75)90044-5 · Cited by 6,873
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
Fred Saad, C., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P. N., Lacombe, L., Chin, J. L., Vinholes, J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,648
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575
Self-citation
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Kantoff, P. W., Halabi, S., Conaway, M. R., Picus, J., Kirshner, J., Hárs, V., Trump, D. L., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 887
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00459-7 · Cited by 696
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407
Self-citation
Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780
Savarese, D. M. F., Halabi, S., Hárs, V., Akerley, W., Taplin, M., Godley, P. A., Hussain, A., Small, E. J., & Vogelzang, N. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2509 · Cited by 322
Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer
Beer, T. M., Eilers, K. M., Garzotto, M. G., Egorin, M. J., Lowe, B. A., & Henner, W. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.117 · Cited by 253
Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain
Ernst, D. S., Tannock, I. F., Winquist, E., Venner, P. M., Reyno, L. M., Moore, M. J., Chi, K. N., Ding, K., Elliott, C., & Parulekar, W. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.042 · Cited by 246
Self-citation

Flagged first, then by citations

Show all 28 references

1 of the 28 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Friedland D, 1999, Semin Oncol, 26, 19
Picus J, 1999, Semin Oncol, 26, 14

Sorted by citations

Items 401–500 of 1,006

Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy
Barlow, L. J., McKiernan, J. M., & Benson, M. C. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.10.068 · Cited by 121
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
Michalski, K., Ruf, J., Goetz, C., Seitz, A. K., Buck, A. K., Lapa, C., & Hartrampf, P. E. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05160-8 · Cited by 121
Acid Ceramidase Upregulation in Prostate Cancer Cells Confers Resistance to Radiation: AC Inhibition, a Potential Radiosensitizer
Mahdy, A. E. M., Cheng, J., Li, J., Elojeimy, S. N., Meacham, W. D., Turner, L. S., Bai, A., Gault, C. R., McPherson, A. S., Garcia, N., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.281 · Cited by 120
Therapeutic targeting of the prostate cancer microenvironment
Κάρλου, Μ., Tzelepi, V., & Efstathiou, E. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.134 · Cited by 122
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016
VanderWalde, N. A., Jagsi, R., Dotan, E., Baumgartner, J. M., Browner, I. S., Burhenn, P., Cohen, H. J., Edil, B. H., Edwards, B. J.-A., Extermann, M., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0146 · Cited by 120
Relevance of randomised controlled trials in oncology
Tannock, I. F., Amir, E., Booth, C. M., Niraula, S., Ocaña, A., Šeruga, B., Templeton, A. J., & Vera-Badillo, F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30572-1 · Cited by 121
Self-citation
Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
Pchejetski, D., Doumerc, N., Golzio, M., Naymark, M., Teissié, J., Kohama, T., Waxman, J., Malavaud, B. A., & Cuvillier, O. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2322 · Cited by 120
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
Fizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119
Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer
Li, Y., Küçük, Ö., Hussain, M., Abrams, J., Cher, M. L., & Sarkar, F. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3752 · Cited by 119
Retracted
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
Tucci, M., Bertaglia, V., Vignani, F., Buttigliero, C., Fiori, C., Porpiglia, F., Scagliotti, G. V., & Maïo, M. D. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.013 · Cited by 121
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
Chi, K. N., Ellard, S. L., Hotte, S. J., Czaykowski, P. M., Moore, M. J., Ruether, J. D., Schell, A. J., Taylor, S., Hansen, C., Gauthier, I., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm554 · Cited by 119
Self-citation
Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
Mittal, K., Donthamsetty, S., Kaur, R., Yang, C., Gupta, M. V., Reid, M. D., Choi, D. H., Rida, P. C. G., & Aneja, R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.78 · Cited by 119
Immunogenicity of anthracyclines: moving towards more personalized medicine
Apétoh, L., Mignot, G., Panaretakis, T., Kroemer, G., & Zitvogel, L. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.002 · Cited by 130
Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
Nilsson, S. F., Franzén, L., Parker, C. C., Tyrrell, C., Blom, R., Tennvall, J., Lennernäs, B., Petersson, U., Johannessen, D. C., Sokal, M., et al. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.07.002 · Cited by 118
Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancer
Aragon‐Ching, J. B., Jain, L., Gulley, J. L., Arlen, P. M., Wright, J. J., Steinberg, S. M., Draper, D., Venitz, J., Jones, E. C., Chen, C. C., et al. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08327.x · Cited by 118
The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors
Lipton, A., Uzzo, R. G., Amato, R. J., Ellis, G. K., Hakimian, B., Roodman, G. D., & Smith, M. R. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0080 · Cited by 120
Obesity and survival after radical prostatectomy: A 10‐year prospective cohort study
Siddiqui, S. A., Inman, B. A., Sengupta, S., Slezak, J. M., Bergstralh, E. J., Leibovich, B. C., Zincke, H., & Blute, M. L. (2006) · Cancer · doi:10.1002/cncr.22030 · Cited by 118
Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy
Morris, M. J., Akhurst, T., Larson, S. M., Ditullio, M., Chu, E., Siedlecki, K. L., Verbel, D., Heller, G., Kelly, W. K., Slovin, S. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2034 · Cited by 118
Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research
Gulley, J. L., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2656 · Cited by 118
Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone
Holzapfel, B. M., Wagner, F., Loessner, D., Holzapfel, N. P., Thibaudeau, L., Crawford, R., Ling, M., Clements, J. A., Russell, P. J., & Hutmacher, D. W. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.062 · Cited by 116
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
Brasso, K., Thomsen, F. B., Schrader, A. J., Schmid, S. C., Lorente, D., Retz, M. M., Merseburger, A. S., von Klot, C. A., Boegemann, M., & Bono, J. S. D. (2014) · European Urology · doi:10.1016/j.eururo.2014.07.028 · Cited by 120
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223 Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
Chittenden, S. J., Hindorf, C., Parker, C. C., Lewington, V. J., Pratt, B. E., Johnson, B., & Flux, G. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157123 · Cited by 118
Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH
Moreira, D. M., Howard, L. E., Sourbeer, K. N., Amarasekara, H. S., Chow, L. C., Cockrell, D. C., Pratson, C. L., Hanyok, B. T., Aronson, W. J., Kane, C. J., et al. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.08.018 · Cited by 117
Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells
Patterson, S. G., Wei, S., Chen, X., Sallman, D. A., Gilvary, D. L., Zhong, B., Pow‐Sang, J. M., Yeatman, T., & Djeu, J. Y. (2006) · Oncogene · doi:10.1038/sj.onc.1209632 · Cited by 117
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Waeckerle‐Men, Y., Allmen, E. U.-V., Fopp, M., von Moos, R., Böhme, C., Schmid, H., Ackermann, D., Cerny, T., Ludewig, B., Groettrup, M., et al. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0157-3 · Cited by 116
Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone
Nelson, J. B., Fizazi, K. S., Miller, K., Higano, C. S., Moul, J. W., Akaza, H., Morris, T., McIntosh, S., Pemberton, K., & Gleave, M. E. (2012) · Cancer · doi:10.1002/cncr.27674 · Cited by 116
Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway
Singh, S. P., Chitkara, D., Mehrazin, R., Behrman, S. W., Wake, R. W., & Mahato, R. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040021 · Cited by 115
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression
Bolis, M., Bossi, D., Vallerga, A., Ceserani, V., Cavalli, M., Impellizzieri, D., Rito, L. D., Zoni, E., Mosole, S., Elia, A. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26840-5 · Cited by 124
Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression
Rybak, A. P., Bristow, R. G., & Kapoor, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2953 · Cited by 122
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel
Ross, R. W., Beer, T. M., Jacobus, S. J., Bubley, G. J., Taplin, M., Ryan, C. W., Huang, J., & Oh, W. K. (2007) · Cancer · doi:10.1002/cncr.23195 · Cited by 115
Biomarkers in Pancreatic Cancer
Fong, Z. V., & Winter, J. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31827654ea · Cited by 116
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., Asahi, S., Miki, H., Tasaka, A., & Kusaka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.01.001 · Cited by 113
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
Harrison, M. R., George, D. J., Wong, & Armstrong, A. J. (2013) · Cancer Management and Research · doi:10.2147/cmar.s25537 · Cited by 117
Senior Adult Oncology
Hurria, A., Browner, I. S., Cohen, H. J., Denlinger, C. S., deShazo, M., Extermann, M., Ganti, A. K., Holland, J. C., Holmes, H. M., Karlekar, M. B., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0019 · Cited by 115
Prostate Cancer: Current Treatment and Prevention Strategies
Chen, F., & Zhao, X. (2013) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.6499 · Cited by 114
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
Yadav, M. P., Ballal, S., Bal, C., Sahoo, R. K., Damle, N. A., Tripathi, M., & Seth, A. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002833 · Cited by 115
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
Fizazi, K. S., Maître, A. L., Hudes, G. R., Berry, W. R., Kelly, W. K., Eymard, J., Logothetis, C. J., Pignon, J., & Michiels, S. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70284-x · Cited by 114
Self-citation
Overcoming Drug Resistance and Treating Advanced Prostate Cancer
Semenas, J., Allegrucci, C., Boorjian, S. A., Mongan, N. P., & Persson, J. L. (2012) · Current Drug Targets · doi:10.2174/138945012802429615 · Cited by 115
Arginine-Terminated Generation 4 PAMAM Dendrimer as an Effective Nanovector for Functional siRNA Delivery in Vitro and in Vivo
Liu, C., Liu, X., Rocchi, P., Qu, F., Iovanna, J., & Peng, L. (2014) · Bioconjugate Chemistry · doi:10.1021/bc4005156 · Cited by 113
Support Ellagic Acid Therapy in Patients with Hormone Refractory Prostate Cancer (HRPC) on Standard Chemotherapy Using Vinorelbine and Estramustine Phosphate
Falsaperla, M., Morgia, G., Tartarone, A., Ardito, R., & Romano, G. (2004) · European Urology · doi:10.1016/j.eururo.2004.12.001 · Cited by 113
The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node–Positive Prostate Cancer: A Systematic Review of the Literature
Gakis, G., Boorjian, S. A., Briganti, A., Joniau, S., Karazanashvili, G., Karnes, R. J., Mattei, A., Shariat, S. F., Stenzl, A., Wirth, M. P., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.033 · Cited by 113
Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
Halabi, S., Vogelzang, N. J., Ou, S., Owzar, K., Archer, L. E., & Small, E. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9159 · Cited by 113
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 114
The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics
Fitzgerald, K. A., Guo, J., Tierney, E. G., Curtin, C. M., Malhotra, M., Darcy, R., O’Brien, F. J., & O’Driscoll, C. M. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.019 · Cited by 112
In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen
Wang, X., Ma, D., Olson, W. C., & Heston, W. D. W. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0191 · Cited by 113
Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling
Molina, A., & Belldegrun, A. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.10.042 · Cited by 112
Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy
Sowery, R. D., Hadaschik, B. A., So, A., Zoubeidi, A., Fazli, L., Hurtado‐Coll, A., & Gleave, M. E. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07618.x · Cited by 112
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
Mehra, N., Dolling, D. I., Sumanasuriya, S., Christova, R., Pope, L., Carreira, S., Seed, G., Yuan, W., GOODALL, J. C., Hall, E., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.02.013 · Cited by 112
Self-citation
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
Westdorp, H., Creemers, J. H. A., van Oort, I. M., Schreibelt, G., Gorris, M. A. J., Mehra, N., Simons, M., de Goede, A. L., van Rossum, M. M., Croockewit, A. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0787-6 · Cited by 114
Identifying Patients at Risk for Significant Versus Clinically Insignificant Postoperative Prostate-Specific Antigen Failure
D'Amico, A. V., Chen, M., Roehl, K. A., & Catàlona, W. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.904 · Cited by 112
Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
Marín‐Aguilera, M., Codony‐Servat, J., Kalko, S. G., Fernández, P. L., Bermudo, R., Buxó, E., Ribal, M. J., Gascón, P., & Mellado, B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0289 · Cited by 111
A retrospective study of the time to clinical endpoints for advanced prostate cancer
Sharifi, N., Dahut, W. L., Steinberg, S. M., Figg, W. D., Tarassoff, C. P., Arlen, P. M., & Gulley, J. L. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05798.x · Cited by 111
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
Rathkopf, D. E., Wong, B. Y., Ross, R. W., Anand, A., Tanaka, E., Woo, M. M., Hu, J. R., Dzik-Jurasz, A., Yang, W., & Scher, H. I. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1289-x · Cited by 111
Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer
Kawakami, K., Fujita, Y., Matsuda, Y., Arai, T., Horie, K., Kameyama, K., Kato, T., Masunaga, K., Kasuya, Y., Tanaka, M., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3301-x · Cited by 113
Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score
Lam, J. S., Seligson, D. B., Yu, H., Ai, L., Eeva, M., Pantuck, A. J., ZENG, G., Horvath, S., & Belldegrun, A. S. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06224.x · Cited by 111
Hyperglycemia During Chemotherapy for Hematologic and Solid Tumors Is Correlated With Increased Toxicity
Brunello, A., Kapoor, R., & Extermann, M. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181e1d0c0 · Cited by 110
Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Auchus, R. J., Yu, M. K., Nguyen, S., & Mundle, S. D. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0167 · Cited by 116
Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
Amaral, T. M. S., Macedo, D., Fernandes, I., & Costa, L. (2012) · Prostate Cancer · doi:10.1155/2012/327253 · Cited by 117
Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
Kahn, B., Collazo, J., & Kyprianou, N. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8671 · Cited by 110
Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom
Fendler, W. P., Kratochwil, C., Ahmadzadehfar, H., Rahbar, K., Baum, R. P., Schmidt, M. C., Pfestroff, A., Lützen, U., Prasad, V., Heinzel, A., et al. (2016) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0037-1616480 · Cited by 113
Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment
Mansinho, A., Macedo, D., Fernandes, I., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-99286-0_7 · Cited by 113
Cancer Immunotherapy: Sipuleucel‐T and Beyond
Hammerstrom, A. E., Cauley, D. H., Atkinson, B. J., & Sharma, P. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.8.813 · Cited by 113
Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study
Lord, R., Nair, S., Schache, A. G., Spicer, J. F., Somaihah, N., Khoo, V. S., & Pandha, H. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.143 · Cited by 110
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
Harrison, M. R., Hahn, N. M., Пили, Р., Oh, W. K., Hammers, H. J., Sweeney, C. J., Kim, K., Perlman, S. B., Arnott, J., Sidor, C. F., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9455-x · Cited by 110
MicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells
Lee, C., Rennie, P. S., & Jia, W. W.-G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0051 · Cited by 111
Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer de la prostate
Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ouzzane, A., Ploussard, G., Azria, D., et al. (2016) · The French Journal of Urology · doi:10.1016/s1166-7087(16)30705-9 · Cited by 114
Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras
Li, P., Wong, Y., Armstrong, K., Haas, N. B., Subedi, P., Davis-Cerone, M., & Doshi, J. A. (2015) · Cancer Medicine · doi:10.1002/cam4.574 · Cited by 107
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
Benoist, G. E., Hendriks, R. J., Mulders, P., Gerritsen, W. R., Somford, D. M., Schalken, J. A., van Oort, I. M., Burger, D. M., & van Erp, N. P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0403-6 · Cited by 107
The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis
Mei, W., Lin, X., Kapoor, A., Gu, Y. J., Zhao, K., & Tang, D. (2019) · Cancers · doi:10.3390/cancers11040434 · Cited by 110
Cancer of the prostate
Sergio Bracarda, A., COBELLI, O. D., Greco, C., Prayer‐Galetti, T., Valdagni, R., Gatta, G., de Braud, F., & Bartsch, G. C. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.010 · Cited by 109
Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer
Wang, L., Rotnitzky, A., Lin, X., Millikan, R. E., & Thall, P. F. (2012) · Journal of the American Statistical Association · doi:10.1080/01621459.2011.641416 · Cited by 108
“…and van der Laan 2007) and comparison of the regimens used in the trial to a particular combination chemotherapy reported in the medical literature while the trial was still ongoing (Tannock et al. 2004; Armstrong and Eisenberger 2006; Armstrong et al. 2007; Millikan, Logothetis, and Thall 2008).”
Result
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., Scheper, R. J., Gerritsen, W. R., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0031-3 · Cited by 107
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
Parker, C. C., Coleman, R. E., Sartor, O. A., Vogelzang, N. J., Bottomley, D., Heinrich, D. A., Helle, S. I., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.021 · Cited by 108
Self-citation
Mechanisms of Non-Opioid Analgesics Beyond Cyclooxygenase Enzyme Inhibition
Hamza, M., & Dionne, R. A. (2009) · Current Molecular Pharmacology · doi:10.2174/1874467210902010001 · Cited by 113
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II trial
James, N. D., Caty, A., Payne, H. A., Borre, M., Zonnenberg, B. A., Beuzeboc, P., McIntosh, S., Morris, T., Phung, D., & Dawson, N. A. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09638.x · Cited by 107
Self-citation
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
Berthold, D., Pond, G. R., de Wit, R., Eisenberger, M. A., & Tannock, I. F. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn288 · Cited by 107
Self-citation
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
Lozano, R., Castro, E., Aragón, I. M., Cendón, Y., Cattrini, C., Lopez-Casas, P. P., & Olmos, D. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01114-x · Cited by 110
Prostate epithelial stem cells
Rizzo, S., Attard, G., & Hudson, D. L. (2005) · Cell Proliferation · doi:10.1111/j.1365-2184.2005.00356.x · Cited by 106
Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy
Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., Wang, J., Derynck, M. K., Ng, K., Lyons, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0649 · Cited by 107
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
Decker, K. F., Zheng, D., He, Y., Bowman, T. A., Edwards, J. R., & Li, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks888 · Cited by 106
Recent trends in the management of advanced prostate cancer
Ritch, C. R., & Cookson, M. S. (2018) · F1000Research · doi:10.12688/f1000research.15382.1 · Cited by 102
C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer
Beer, T. M., Lalani, A. S., Lee, S. J., Mori, M., Eilers, K. M., Curd, J. G., Henner, W. D., Ryan, C. W., Venner, P. M., Ruether, J. D., et al. (2008) · Cancer · doi:10.1002/cncr.23461 · Cited by 106
Self-citation
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T‐cells
Morgenroth, A., Cartellieri, M., Schmitz, M., Günes, S., Weigle, B., Bachmann, M. P., Abken, H., Rieber, E. P., & Temme, A. (2007) · The Prostate · doi:10.1002/pros.20608 · Cited by 106
Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells
Yacqub‐Usman, K., Pickard, M. R., & Williams, G. T. (2015) · The Prostate · doi:10.1002/pros.22952 · Cited by 105
A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer
Prue, R. L., Vari, F., Radford, K. J., Tong, H., Hardy, M. Y., D’Rozario, R., Waterhouse, N. J., Rossetti, T. R., Coleman, R., Tracey, C., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000063 · Cited by 108
Src signaling pathways in prostate cancer
Varkaris, A. S., Κατσιαμπούρα, Α., Araujo, J. C., Gallick, G. E., & Corn, P. G. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9481-1 · Cited by 109
Brain Metastases from Prostate Cancer: An 11‐Year Analysis in the MRI Era with Emphasis on Imaging Characteristics, Incidence, and Prognosis
Hatzoglou, V., Patel, G. V., Morris, M. J., Curtis, K. R., Zhang, Z., Shi, W., Huse, J. T., Rosenblum, M. K., Holodny, A. I., & Young, R. J. (2012) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2012.00767.x · Cited by 105
Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
Halabi, S., Armstrong, A. J., Sartor, O. A., Bono, J. S. D., Kaplan, E. B., Lin, C., Solomon, N. C., & Small, E. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3201 · Cited by 106
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis
Wallis, C. J. D., Klaassen, Z. W. A., Bhindi, B., Goldberg, H., Chandrasekar, T., Farrell, A. M., Boorjian, S. A., Kulkarni, G. S., Karnes, R. J., & Satkunasivam, R. (2017) · European Urology · doi:10.1016/j.eururo.2017.10.002 · Cited by 107
Clusterin and Chemoresistance
Djeu, J. Y., & Wei, S. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)05005-2 · Cited by 106
TROPIC: Phase III Trial of Cabazitaxel for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Oudard, S. M. (2011) · Future Oncology · doi:10.2217/fon.11.23 · Cited by 105
Self-citation
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
Steinbild, S., Mross, K. B., Frost, A., Morant, R., Gillessen, S., Dittrich, C., Strumberg, D., Hochhaus, A., Hanauske, A.-R., Edler, L., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604064 · Cited by 104
Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress
Whitaker, H. C., Patel, D., Howat, W., Warren, A. Y., Kay, J. D., Sangan, T., Marioni, J. C., Mitchell, J., Aldridge, S., Luxton, H. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.396 · Cited by 106
Treating Prostate Cancer by Antibody–Drug Conjugates
Rosellini, M., Santoni, M., Mollica, V., Rizzo, A., Cimadamore, A., Scarpelli, M., Storti, N., Battelli, N., Montironi, R., & Massari, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041551 · Cited by 106
A Feasibility Study Evaluating the Functional Diffusion Map as a Predictive Imaging Biomarker for Detection of Treatment Response in a Patient with Metastatic Prostate Cancer to the Bone
Lee, K. C., Bradley, D., Hussain, M., Meyer, C. R., Chenevert, T. L., Jacobson, J. A., Johnson, T. D., Galbán, C. J., Rehemtulla, A., Pienta, K. J., et al. (2007) · Neoplasia · doi:10.1593/neo.07954 · Cited by 103
Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P., Marx, G. M., Pavlakis, N., Boyer, M. J., Stockler, M. R., Kaplan, W. H., Breit, S. N., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4901 · Cited by 105
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
Fotin‐Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. M., & Kallen, K. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2605 · Cited by 103
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
Goodman, O. B., Flaig, T. W., Molina, A., Mulders, P., Fizazi, K. S., Suttmann, H., Li, J., Kheoh, T. S., Bono, J. S. D., & Scher, H. I. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.41 · Cited by 103
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
Heidenreich, A., Sergio Bracarda, A., Mason, M. D., Özen, H., Sengeløv, L., van Oort, I. M., Papandreou, C. N., Fosså, S. D., Hitier, S., & Climent, M. Á. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.006 · Cited by 104
Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer
Franke, R. M., Carducci, M. A., Rudek, M. A., Baker, S. D., & Sparreboom, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7025 · Cited by 103

Authors: Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., Rosenthal, M. A., & Eisenberger, M. A.
Affiliations: University of Toronto (CA)
National Institute of Oncology (HU)
Medical University of Lodz (PL)
BC Cancer Agency (CA)
Institut Gustave Roussy (FR)
Cancer Research UK (GB)
Uppsala University Hospital (SE)
Cancer Trials Australia (AU)
Johns Hopkins University (US)
ORCID: Tannock, Ian F.
Chi, Kim N.
James, Nicholas D.
Turesson, Ingela
Rosenthal, Mark A.
Eisenberger, Mario A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2004-10-07
Volume: 351
Issue: 15
Pages: 1502-1512
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa040720
OpenAlex: W2120292596
Cited by: 5,735
References: 28
Citations by year: 2026: 97 · 2025: 132 · 2024: 191 · 2023: 172 · 2022: 226 · 2021: 273 · 2020: 267 · 2019: 243 · 2018: 277 · 2017: 278 · 2016: 323 · 2015: 337 · 2014: 342 · 2013: 370 · 2012: 392
FWCI: 187.05
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords: docetaxel, mitoxantrone, prednisone, castration-resistant prostate cancer, metastatic prostate cancer, overall survival, prostate-specific antigen, pain, quality of life, chemotherapy schedule, adverse events, corticosteroids, androgen deprivation therapy, taxanes, anthracyclines, randomized trial comparison, treatment-related morbidity
MeSH terms: Docetaxel, Adenocarcinoma, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Follow-Up Studies, Humans, Male, Middle Aged, Mitoxantrone, Prednisone, Prostatic Neoplasms, Quality of Life, Survival Analysis, Drug Resistance, Neoplasm, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks